Pediatric Eye Disease Investigator Group (PEDIG)

Protocol: ROP1 - Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
Status: Recruiting
Start Date: 04/28/2015
End Date: 09/15/2016
Clinical Trial ID: NCT02390531
Public Dataset:  


Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
?

Protocol
Injection Procedure manual

 

Primary Objective:

  • The primary objective of the study is to determine a dose of a single intravitreal bevacizumab injection that is effective and is lower than currently used for treatment of severe (type 1) ROP.



Back

© 2007 -2017 Jaeb Center for Health Research
All forms and reports on this site require Adobe Acrobat Reader. Click HERE to download a free copy of Adobe.
Although JCHR supports various web browsers, only Internet Explorer version 11 is fully tested and validated to function on this site.
This site utilizes popup windows.